Climb Bio (CLYM) announced that the FDA has granted Fast Track Designation to budoprutug, the company’s investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy-a rare kidney disease for which there are currently no FDA-approved treatments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: